Notice: This company has been marked as potentially delisted and may not be actively trading.

Fusion Pharmaceuticals (FUSN) Stock Forecast & Price Target

Get the Latest News and Ratings for FUSN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Fusion Pharmaceuticals and its competitors.

FUSN Analyst Ratings Over Time

Type	Current Forecast 10/7/23 to 10/6/24	1 Month Ago 9/7/23 to 9/6/24	3 Months Ago 7/9/23 to 7/8/24	1 Year Ago 10/7/22 to 10/7/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	6 Buy rating(s)
Hold	13 Hold rating(s)	13 Hold rating(s)	13 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$20.25	$20.25	$20.25	$10.80
Forecasted Upside	-6.03% Downside	-6.03% Downside	-6.03% Downside	188.00% Upside
Consensus Rating	Hold	Hold	Hold	Buy

Next opportunity for crypto millions (Ad)

October isn't just another month in crypto. It's the launchpad for what could be the most explosive bull run in history. And I've found the rocket fuel… One coin is quietly positioning itself to outperform the entire market. The signs are everywhere…

Go here to discover the coin that could define this historic bull run with gains kicking off this mo

FUSN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

FUSN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Fusion Pharmaceuticals Stock vs. The Competition

Type	Fusion Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.07	2.79	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	-6.03% Downside	10,592.03% Upside	7.04% Upside
News Sentiment Rating	Neutral News See Recent FUSN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/16/2024	TD Cowen 4 of 5 stars		Reiterated Rating	Buy ➝ Hold
3/20/2024	Bloom Burton 2 of 5 stars	D. Martin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
3/20/2024	B. Riley 4 of 5 stars	Y. Zhi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$13.00 ➝ $23.00	+8.75%
3/20/2024	Jonestrading Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
3/20/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Sector Perform	$16.00 ➝ $21.00	-0.85%
3/19/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	F. Khurshid Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
Get the Latest News and Ratings for FUSN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
3/19/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold	$11.00 ➝ $21.00	-0.05%
3/19/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold	$10.00 ➝ $21.00	+0.05%
3/19/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Strong-Buy ➝ Market Perform
3/19/2024	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Dolliver Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
3/19/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hsieh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/19/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Nierengarten Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$24.00	+14.29%
3/19/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Market Perform	$17.00 ➝ $21.00	+97.37%
1/5/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$13.00 ➝ $15.00	+77.94%
1/27/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$19.00 ➝ $10.00	+201.20%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 09:27 AM ET.

FUSN Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Fusion Pharmaceuticals is $20.25, with a high forecast of $24.00 and a low forecast of $15.00.
: 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last twelve months. There are currently 13 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" FUSN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FUSN, but not buy additional shares or sell existing shares.
: According to analysts, Fusion Pharmaceuticals's stock has a predicted downside of -6.03% based on their 12-month stock forecasts.
: Analysts like Fusion Pharmaceuticals less than other "medical" companies. The consensus rating for Fusion Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how FUSN compares to other companies.